Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.6% in the second quarter, Holdings Channel.com reports. The fund owned 912,000 shares of the company’s stock after acquiring an additional 101,747 shares during the quarter. Nurix Therapeutics makes up approximately 2.2% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 9th biggest position. Affinity Asset Advisors LLC’s holdings in Nurix Therapeutics were worth $19,033,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. ProShare Advisors LLC raised its holdings in shares of Nurix Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the last quarter. ClariVest Asset Management LLC raised its position in Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock valued at $1,318,000 after purchasing an additional 1,766 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of Nurix Therapeutics by 3.7% during the first quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after buying an additional 1,820 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NRIX. Oppenheimer lifted their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. HC Wainwright increased their price objective on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, June 18th. Truist Financial started coverage on Nurix Therapeutics in a research report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price objective on the stock. Needham & Company LLC dropped their price objective on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a report on Friday, July 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $35.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $27.00.

Insider Transactions at Nurix Therapeutics

In related news, insider Christine Ring sold 9,050 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $24.94, for a total value of $225,707.00. Following the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $613,324.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the transaction, the chief financial officer now owns 31,002 shares in the company, valued at approximately $781,870.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christine Ring sold 9,050 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $24.94, for a total value of $225,707.00. Following the sale, the insider now owns 24,592 shares of the company’s stock, valued at approximately $613,324.48. The disclosure for this sale can be found here. Insiders sold a total of 59,815 shares of company stock valued at $1,416,751 over the last three months. 7.20% of the stock is currently owned by insiders.

Nurix Therapeutics Trading Up 0.7 %

Shares of NRIX opened at $24.28 on Wednesday. Nurix Therapeutics, Inc. has a one year low of $4.22 and a one year high of $26.31. The stock has a 50 day moving average price of $22.99 and a 200 day moving average price of $18.40.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). The firm had revenue of $12.09 million during the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.